Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using γ-H2AX foci of DNA damage in lymphocytes

Mariko Doai; Naoto Watanabe; Tomoko Takahashi; Mitsuru Taniguchi; Hisao Tonami; Kuniyoshi Iwabuchi; Daiki Kayano; Makoto Fukuoka; Seigo Kinuya

doi:10.1007/s12149-012-0678-0

Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using γ-H2AX foci of DNA damage in lymphocytes

Mariko Doai^*, Naoto Watanabe, Tomoko Takahashi, Mitsuru Taniguchi, Hisao Tonami, Kuniyoshi Iwabuchi, Daiki Kayano, Makoto Fukuoka, Seigo Kinuya

^*Corresponding author for this work

Diagnostic and Therapeutic Radiology

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Purpose: The purpose of our study was to evaluate the degree of radiotoxicity to lymphocytes in thyroid cancer after iodine-131(I-131) therapy using γ-H2AX foci immunodetection. Methods: This study focused on 15 patients who underwent I-131 therapy for differentiated thyroid cancer after surgery. All patients received 3.7 GBq of I-131. Venous blood samples were collected from each patient before therapy and 4 days thereafter. Lymphocytes were isolated from the blood samples and subjected to γ-H2AX immunofluorescence staining. Results: The number (mean ± SD) of foci per lymphocyte nucleus was 0.41 ± 0.51 before and 6.19 ± 1.80 after radioiodine therapy, and this difference was statistically significant (P = 0.001 < 0.05). Absorbed doses estimated for the 15 patients were 0.77 ± 0.31 Gy applying standard line in vitro external radiation doses. Conclusion: γ-H2AX foci immunodetection in lymphocytes may detect radiation-induced DNA damage associated with I-131 therapy for thyroid cancer, and may facilitate estimation of the radiation doses absorbed with this therapy.

Original language	English
Pages (from-to)	233-238
Number of pages	6
Journal	Annals of Nuclear Medicine
Volume	27
Issue number	3
DOIs	https://doi.org/10.1007/s12149-012-0678-0
State	Published - 2013/04

Keywords

DNA damage
Radioiodine-131 therapy
Radiotoxicity
γ-H2AX

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12149-012-0678-0

Cite this

@article{9166198bc3e940e692dc88b9b0683d2d,

title = "Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using γ-H2AX foci of DNA damage in lymphocytes",

abstract = "Purpose: The purpose of our study was to evaluate the degree of radiotoxicity to lymphocytes in thyroid cancer after iodine-131(I-131) therapy using γ-H2AX foci immunodetection. Methods: This study focused on 15 patients who underwent I-131 therapy for differentiated thyroid cancer after surgery. All patients received 3.7 GBq of I-131. Venous blood samples were collected from each patient before therapy and 4 days thereafter. Lymphocytes were isolated from the blood samples and subjected to γ-H2AX immunofluorescence staining. Results: The number (mean ± SD) of foci per lymphocyte nucleus was 0.41 ± 0.51 before and 6.19 ± 1.80 after radioiodine therapy, and this difference was statistically significant (P = 0.001 < 0.05). Absorbed doses estimated for the 15 patients were 0.77 ± 0.31 Gy applying standard line in vitro external radiation doses. Conclusion: γ-H2AX foci immunodetection in lymphocytes may detect radiation-induced DNA damage associated with I-131 therapy for thyroid cancer, and may facilitate estimation of the radiation doses absorbed with this therapy.",

keywords = "DNA damage, Radioiodine-131 therapy, Radiotoxicity, γ-H2AX",

author = "Mariko Doai and Naoto Watanabe and Tomoko Takahashi and Mitsuru Taniguchi and Hisao Tonami and Kuniyoshi Iwabuchi and Daiki Kayano and Makoto Fukuoka and Seigo Kinuya",

note = "Funding Information: Acknowledgments This study was supported in part by a Grant-in-Aid for scientific research from the Japan Society for the promotion of Science, Grant for Collaborative Research from Kanazawa Medical University (C2009-5,C2010-3), Grant for Project Research from High-Tech Research Center of Kanazawa Medical University (H2010-10, H2011-10), Assist KAKEN from Kanazawa Medical University and Hokkoku foundation for cancer research.",

year = "2013",

month = apr,

doi = "10.1007/s12149-012-0678-0",

language = "英語",

volume = "27",

pages = "233--238",

journal = "Annals of Nuclear Medicine",

issn = "0914-7187",

publisher = "Springer Japan",

number = "3",

}

TY - JOUR

T1 - Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using γ-H2AX foci of DNA damage in lymphocytes

AU - Doai, Mariko

AU - Watanabe, Naoto

AU - Takahashi, Tomoko

AU - Taniguchi, Mitsuru

AU - Tonami, Hisao

AU - Iwabuchi, Kuniyoshi

AU - Kayano, Daiki

AU - Fukuoka, Makoto

AU - Kinuya, Seigo

N1 - Funding Information: Acknowledgments This study was supported in part by a Grant-in-Aid for scientific research from the Japan Society for the promotion of Science, Grant for Collaborative Research from Kanazawa Medical University (C2009-5,C2010-3), Grant for Project Research from High-Tech Research Center of Kanazawa Medical University (H2010-10, H2011-10), Assist KAKEN from Kanazawa Medical University and Hokkoku foundation for cancer research.

PY - 2013/4

Y1 - 2013/4

N2 - Purpose: The purpose of our study was to evaluate the degree of radiotoxicity to lymphocytes in thyroid cancer after iodine-131(I-131) therapy using γ-H2AX foci immunodetection. Methods: This study focused on 15 patients who underwent I-131 therapy for differentiated thyroid cancer after surgery. All patients received 3.7 GBq of I-131. Venous blood samples were collected from each patient before therapy and 4 days thereafter. Lymphocytes were isolated from the blood samples and subjected to γ-H2AX immunofluorescence staining. Results: The number (mean ± SD) of foci per lymphocyte nucleus was 0.41 ± 0.51 before and 6.19 ± 1.80 after radioiodine therapy, and this difference was statistically significant (P = 0.001 < 0.05). Absorbed doses estimated for the 15 patients were 0.77 ± 0.31 Gy applying standard line in vitro external radiation doses. Conclusion: γ-H2AX foci immunodetection in lymphocytes may detect radiation-induced DNA damage associated with I-131 therapy for thyroid cancer, and may facilitate estimation of the radiation doses absorbed with this therapy.

AB - Purpose: The purpose of our study was to evaluate the degree of radiotoxicity to lymphocytes in thyroid cancer after iodine-131(I-131) therapy using γ-H2AX foci immunodetection. Methods: This study focused on 15 patients who underwent I-131 therapy for differentiated thyroid cancer after surgery. All patients received 3.7 GBq of I-131. Venous blood samples were collected from each patient before therapy and 4 days thereafter. Lymphocytes were isolated from the blood samples and subjected to γ-H2AX immunofluorescence staining. Results: The number (mean ± SD) of foci per lymphocyte nucleus was 0.41 ± 0.51 before and 6.19 ± 1.80 after radioiodine therapy, and this difference was statistically significant (P = 0.001 < 0.05). Absorbed doses estimated for the 15 patients were 0.77 ± 0.31 Gy applying standard line in vitro external radiation doses. Conclusion: γ-H2AX foci immunodetection in lymphocytes may detect radiation-induced DNA damage associated with I-131 therapy for thyroid cancer, and may facilitate estimation of the radiation doses absorbed with this therapy.

KW - DNA damage

KW - Radioiodine-131 therapy

KW - Radiotoxicity

KW - γ-H2AX

UR - http://www.scopus.com/inward/record.url?scp=84880698245&partnerID=8YFLogxK

U2 - 10.1007/s12149-012-0678-0

DO - 10.1007/s12149-012-0678-0

M3 - 学術論文

C2 - 23264066

AN - SCOPUS:84880698245

SN - 0914-7187

VL - 27

SP - 233

EP - 238

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

IS - 3

ER -

Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using γ-H2AX foci of DNA damage in lymphocytes

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this